Cytori Therapeutics, Inc., a cell therapy company, engages in developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular diseases, burns, and other soft tissue injuries. It primarily provides the Celution System, which automates the process of digesting fat tissue, releasing the ADRCs. It also offers the StemSource Cell Bank, a suite of products to allow hospitals or tissue banks to cryopreserve adipose-derived stem and regenerative cells; StemSource 900/MB, a research laboratory equipment; and Puregraft system that is designed to streamline the fat graft preparation process by selectively washing and filtering the tissue to remove contaminants in a closed and sterile field, as well as a range of ancillary products designed to optimize tissue harvest and graft delivery. Its products also include Celution 800 System that has CE Mark approval for certain soft tissue procedures, such as breast reconstruction, tissue ischemia, deficiency or injury of skin, fat, and muscle and fascia, as well as soft tissue wounds or fistulae associated with trauma, diabetes, ischemia, and radiation injury. The company markets its systems, instrumentations, and consumables directly, as well as through a network of distributors to hospitals, plastic surgery clinics, tissue banks, and stem cell banking companies, as well as researchers performing investigator-initiated and funded studies worldwide. Cytori Therapeutics, Inc. was founded in 1996 and is headquartered in San Diego, California.

Key Statistics